136 related articles for article (PubMed ID: 37470344)
1. The rs72613567:TA polymorphism in HSD17B13 is associated with survival benefit after development of hepatocellular carcinoma.
Innes H; Morgan MY; Hampe J; Stickel F; Buch S
Aliment Pharmacol Ther; 2023 Sep; 58(6):623-631. PubMed ID: 37470344
[TBL] [Abstract][Full Text] [Related]
2. Genetic Variation in HSD17B13 Reduces the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol Misusers.
Stickel F; Lutz P; Buch S; Nischalke HD; Silva I; Rausch V; Fischer J; Weiss KH; Gotthardt D; Rosendahl J; Marot A; Elamly M; Krawczyk M; Casper M; Lammert F; Buckley TWM; McQuillin A; Spengler U; Eyer F; Vogel A; Marhenke S; von Felden J; Wege H; Sharma R; Atkinson S; Franke A; Nehring S; Moser V; Schafmayer C; Spahr L; Lackner C; Stauber RE; Canbay A; Link A; Valenti L; Grove JI; Aithal GP; Marquardt JU; Fateen W; Zopf S; Dufour JF; Trebicka J; Datz C; Deltenre P; Mueller S; Berg T; Hampe J; Morgan MY
Hepatology; 2020 Jul; 72(1):88-102. PubMed ID: 31630428
[TBL] [Abstract][Full Text] [Related]
3. Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study.
Trépo E; Caruso S; Yang J; Imbeaud S; Couchy G; Bayard Q; Letouzé E; Ganne-Carrié N; Moreno C; Oussalah A; Féray C; Blanc JF; Clément B; Hillon P; Boursier J; Paradis V; Calderaro J; Gnemmi V; Nault JC; Guéant JL; Devière J; Archambeaud I; Vitellius C; Turlin B; Bronowicki JP; Gustot T; Sutton A; ; Ziol M; Nahon P; Zucman-Rossi J
Lancet Oncol; 2022 Jan; 23(1):161-171. PubMed ID: 34902334
[TBL] [Abstract][Full Text] [Related]
4. Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease.
Paternostro R; Staufer K; Traussnigg S; Stättermayer AF; Halilbasic E; Keritam O; Meyer EL; Stift J; Wrba F; Sipos B; Canbay A; Schlattjan M; Aigner E; Datz C; Stickel F; Schafmayer C; Hampe J; Buch S; Prager G; Munda P; Mandorfer M; Ferenci P; Trauner M
Hepatol Int; 2021 Aug; 15(4):922-933. PubMed ID: 34076851
[TBL] [Abstract][Full Text] [Related]
5. Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis.
Stickel F; Buch S; Nischalke HD; Weiss KH; Gotthardt D; Fischer J; Rosendahl J; Marot A; Elamly M; Casper M; Lammert F; McQuillin A; Zopf S; Spengler U; Marhenke S; Kirstein MM; Vogel A; Eyer F; von Felden J; Wege H; Buch T; Schafmayer C; Braun F; Deltenre P; Berg T; Morgan MY; Hampe J
Am J Gastroenterol; 2018 Oct; 113(10):1475-1483. PubMed ID: 29535416
[TBL] [Abstract][Full Text] [Related]
6. Association of HSD17B13 rs72613567: TA allelic variant with liver disease: review and meta-analysis.
Tang S; Zhang J; Mei TT; Zhang WY; Zheng SJ; Yu HB
BMC Gastroenterol; 2021 Dec; 21(1):490. PubMed ID: 34930143
[TBL] [Abstract][Full Text] [Related]
7. A 17-Beta-Hydroxysteroid Dehydrogenase 13 Variant Protects From Hepatocellular Carcinoma Development in Alcoholic Liver Disease.
Yang J; Trépo E; Nahon P; Cao Q; Moreno C; Letouzé E; Imbeaud S; Bayard Q; Gustot T; Deviere J; Bioulac-Sage P; Calderaro J; Ganne-Carrié N; Laurent A; Blanc JF; Guyot E; Sutton A; Ziol M; Zucman-Rossi J; Nault JC
Hepatology; 2019 Jul; 70(1):231-240. PubMed ID: 30908678
[TBL] [Abstract][Full Text] [Related]
8. [Effects of PNPLA3, TM6SF2 gene polymorphisms and its interactions with smoking and alcohol drinking on hepatitis B virus-associated hepatocellular carcinoma].
Wang LQ; Guo WH; Guo ZW; Qin P; Zhang R; Zhu XM; Liu DW
Zhonghua Liu Xing Bing Xue Za Zhi; 2018 Dec; 39(12):1611-1616. PubMed ID: 30572387
[No Abstract] [Full Text] [Related]
9. PNPLA3 rs738409 and TM6SF2 rs58542926 variants increase the risk of hepatocellular carcinoma in alcoholic cirrhosis.
Falleti E; Cussigh A; Cmet S; Fabris C; Toniutto P
Dig Liver Dis; 2016 Jan; 48(1):69-75. PubMed ID: 26493626
[TBL] [Abstract][Full Text] [Related]
10. Combined Effect of PNPLA3, TM6SF2, and HSD17B13 Variants on Risk of Cirrhosis and Hepatocellular Carcinoma in the General Population.
Gellert-Kristensen H; Richardson TG; Davey Smith G; Nordestgaard BG; Tybjaerg-Hansen A; Stender S
Hepatology; 2020 Sep; 72(3):845-856. PubMed ID: 32190914
[TBL] [Abstract][Full Text] [Related]
11. PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases.
Yang J; Trépo E; Nahon P; Cao Q; Moreno C; Letouzé E; Imbeaud S; Gustot T; Deviere J; Debette S; Amouyel P; Bioulac-Sage P; Calderaro J; Ganne-Carrié N; Laurent A; Blanc JF; Guyot E; Sutton A; Ziol M; Zucman-Rossi J; Nault JC
Int J Cancer; 2019 Feb; 144(3):533-544. PubMed ID: 30289982
[TBL] [Abstract][Full Text] [Related]
12. Genetic variation in
Buch S; Innes H; Lutz PL; Nischalke HD; Marquardt JU; Fischer J; Weiss KH; Rosendahl J; Marot A; Krawczyk M; Casper M; Lammert F; Eyer F; Vogel A; Marhenke S; von Felden J; Sharma R; Atkinson SR; McQuillin A; Nattermann J; Schafmayer C; Franke A; Strassburg C; Rietschel M; Altmann H; Sulk S; Thangapandi VR; Brosch M; Lackner C; Stauber RE; Canbay A; Link A; Reiberger T; Mandorfer M; Semmler G; Scheiner B; Datz C; Romeo S; Ginanni Corradini S; Irving WL; Morling JR; Guha IN; Barnes E; Ansari MA; Quistrebert J; Valenti L; Müller SA; Morgan MY; Dufour JF; Trebicka J; Berg T; Deltenre P; Mueller S; Hampe J; Stickel F
Gut; 2023 Feb; 72(2):381-391. PubMed ID: 35788059
[TBL] [Abstract][Full Text] [Related]
13. Interplay of
De Benedittis C; Bellan M; Crevola M; Boin E; Barbaglia MN; Mallela VR; Ravanini P; Ceriani E; Fangazio S; Sainaghi PP; Burlone ME; Minisini R; Pirisi M
Gastroenterol Res Pract; 2020; 2020():4216451. PubMed ID: 32382265
[TBL] [Abstract][Full Text] [Related]
14. Genetic variant rs72613567 of HSD17B13 gene reduces alcohol-related liver disease risk in Chinese Han population.
Chen H; Zhang Y; Guo T; Yang F; Mao Y; Li L; Liu C; Gao H; Jin Y; Che Y; Li Y; Huang J
Liver Int; 2020 Sep; 40(9):2194-2202. PubMed ID: 33151633
[TBL] [Abstract][Full Text] [Related]
15. Analysis of genetic factors associated with fatty liver disease-related hepatocellular carcinoma.
Kogiso T; Ogasawara Y; Horiuchi K; Taniai M; Tokushige K
Cancer Med; 2023 Sep; 12(17):17798-17807. PubMed ID: 37644826
[TBL] [Abstract][Full Text] [Related]
16. Pediatric non-alcoholic fatty liver disease and kidney function: Effect of
Di Sessa A; Umano GR; Cirillo G; Passaro AP; Verde V; Cozzolino D; Guarino S; Marzuillo P; Miraglia Del Giudice E
World J Gastroenterol; 2020 Sep; 26(36):5474-5483. PubMed ID: 33024398
[TBL] [Abstract][Full Text] [Related]
17. High Risk of Fatty Liver Disease Amplifies the Alanine Transaminase-Lowering Effect of a HSD17B13 Variant.
Gellert-Kristensen H; Nordestgaard BG; Tybjaerg-Hansen A; Stender S
Hepatology; 2020 Jan; 71(1):56-66. PubMed ID: 31155741
[TBL] [Abstract][Full Text] [Related]
18. HSD17B13 rs72613567 protects against liver diseases and histological progression of nonalcoholic fatty liver disease: a systematic review and meta-analysis.
Wang P; Wu CX; Li Y; Shen N
Eur Rev Med Pharmacol Sci; 2020 Sep; 24(17):8997-9007. PubMed ID: 32964989
[TBL] [Abstract][Full Text] [Related]
19. Impact of a Loss-of-Function Variant in
Gil-Gómez A; Rojas Á; García-Lozano MR; Muñoz-Hernández R; Gallego-Durán R; Maya-Miles D; Montero-Vallejo R; Gato S; Gallego J; Francés R; Soriano G; Ampuero J; Romero-Gómez M
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233142
[TBL] [Abstract][Full Text] [Related]
20. The HSD17B13 rs72613567 variant is associated with lower levels of albuminuria in patients with biopsy-proven nonalcoholic fatty liver disease.
Sun DQ; Wang TY; Zheng KI; Zhang HY; Wang XD; Targher G; Byrne CD; Chen YP; Yuan WJ; Jin Y; Zheng MH
Nutr Metab Cardiovasc Dis; 2021 Jun; 31(6):1822-1831. PubMed ID: 33853719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
